United Therapeutics (NASDAQ:UTHR) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of United Therapeutics (NASDAQ:UTHR) in a report released on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $660.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for United Therapeutics’ Q4 2026 earnings at $8.68 EPS, FY2026 earnings at $27.46 EPS, FY2027 earnings at $30.14 EPS, FY2028 earnings at $30.67 EPS, FY2029 earnings at $40.68 EPS and FY2030 earnings at $53.67 EPS.

A number of other analysts have also commented on the company. Raymond James Financial set a $720.00 price target on United Therapeutics in a research note on Wednesday, November 4th. Morgan Stanley upped their price objective on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. Leerink Partners raised their target price on shares of United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a research report on Monday, October 19th. JPMorgan Chase & Co. dropped their target price on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a research report on Wednesday, October 28th. Finally, Weiss Ratings cut shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $676.40.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $595.66 on Monday. The company’s 50 day moving average price is $538.56 and its 200-day moving average price is $535.20. United Therapeutics has a 52-week low of $452.44 and a 52-week high of $614.23. The stock has a market capitalization of $25.37 billion, a price-to-earnings ratio of 22.48, a P/E/G ratio of 3.94 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The business had revenue of $832.50 million for the quarter, compared to the consensus estimate of $781.14 million. During the same period in the previous year, the company earned $7.16 EPS. The company’s revenue for the quarter was up 4.1% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics will post 24.90 earnings per share for the current fiscal year.

United Therapeutics declared that its board has initiated a stock buyback plan on Thursday, October 22nd that allows the company to repurchase $2 billion in shares. This buyback authorization allows the biotechnology company to purchase up to 8.3% of its shares through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other United Therapeutics news, Director Christopher Patusky sold 1,210 shares of United Therapeutics stock in a transaction on Monday, November 9th. The stock was sold at an average price of $580.00, for a total transaction of $701,800.00. Following the completion of the transaction, the director owned 2,140 shares in the company, valued at approximately $1,241,200. The trade was a 36.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Paul Mahon sold 8,300 shares of the business’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $598.67, for a total value of $4,968,961.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at $27,043,121.24. This trade represents a 15.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 412,238 shares of company stock worth $220,071,746 in the last 90 days. Insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Hedge funds have recently bought and sold shares of the company. Advisors Asset Management Inc. purchased a new stake in shares of United Therapeutics during the third quarter valued at approximately $23,850,000. Edmond DE Rothschild Holding S.A. lifted its position in United Therapeutics by 245.8% in the 3rd quarter. Edmond DE Rothschild Holding S.A. now owns 2,932 shares of the biotechnology company’s stock valued at $1,589,000 after acquiring an additional 2,084 shares in the last quarter. Private Wealth Asset Management LLC bought a new position in United Therapeutics in the 3rd quarter valued at approximately $276,000. Private Advisor Group LLC lifted its position in United Therapeutics by 24.6% in the 3rd quarter. Private Advisor Group LLC now owns 1,730 shares of the biotechnology company’s stock valued at $938,000 after acquiring an additional 342 shares in the last quarter. Finally, Focus Advisor Solutions LLC boosted its stake in United Therapeutics by 46.6% during the 3rd quarter. Focus Advisor Solutions LLC now owns 2,151 shares of the biotechnology company’s stock valued at $1,166,000 after purchasing an additional 684 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Key Headlines Impacting United Therapeutics

These are some of the UTHR headlines that stood out recently:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $660 price target, above the share price cited in the background. Its forecasts call for EPS to rise from $27.46 in FY2026 to $53.67 in FY2030, signaling confidence in longer-term earnings growth. HC Wainwright coverage report
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares on November 6 and another 9,500 shares across transactions on November 9. Director Christopher Patusky also sold 1,210 shares, reducing his position by 36.12%. Insider selling can weigh on sentiment, although both executives retain shares. SEC filing

About United Therapeutics

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.